EverSource Wealth Advisors LLC Boosts Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB)

EverSource Wealth Advisors LLC raised its stake in Nuvation Bio Inc. (NYSE:NUVB) by 913.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,095 shares of the company’s stock after acquiring an additional 10,000 shares during the period. EverSource Wealth Advisors LLC’s holdings in Nuvation Bio were worth $32,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Profund Advisors LLC purchased a new stake in shares of Nuvation Bio in the second quarter worth about $63,000. Dimensional Fund Advisors LP raised its holdings in shares of Nuvation Bio by 415.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock worth $2,975,000 after acquiring an additional 820,669 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Nuvation Bio during the 2nd quarter valued at approximately $89,000. American Century Companies Inc. boosted its position in shares of Nuvation Bio by 120.4% during the 2nd quarter. American Century Companies Inc. now owns 243,358 shares of the company’s stock valued at $711,000 after acquiring an additional 132,939 shares during the last quarter. Finally, Choreo LLC purchased a new position in shares of Nuvation Bio in the second quarter valued at $47,000. Institutional investors own 61.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on NUVB shares. Wedbush reiterated an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a research report on Wednesday, September 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $5.00 price target on shares of Nuvation Bio in a research report on Tuesday, August 6th. Finally, HC Wainwright decreased their price objective on Nuvation Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $6.40.

Nuvation Bio Trading Down 3.2 %

Nuvation Bio stock opened at $2.39 on Friday. The firm has a market capitalization of $595.68 million, a PE ratio of -7.71 and a beta of 1.38. Nuvation Bio Inc. has a 12-month low of $0.95 and a 12-month high of $4.16. The firm has a 50-day moving average price of $3.02 and a 200-day moving average price of $3.01.

Nuvation Bio (NYSE:NUVB) last announced its earnings results on Monday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The business had revenue of $1.44 million during the quarter. As a group, sell-side analysts predict that Nuvation Bio Inc. will post -0.4 earnings per share for the current fiscal year.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.